Attico E, Sceberras V, Pellegrini G
1Centre for Regenerative Medicine "Stefano Ferrari", University of Modena and Reggio Emilia, Modena, Italy.
Holostem Terapie Avanzate, Modena, Italy.
Curr Transplant Rep. 2018;5(3):244-250. doi: 10.1007/s40472-018-0202-0. Epub 2018 Aug 2.
This review highlights problems related to translation of advanced therapy medicinal products (ATMPs) from bench to bedsite. Regenerative medicine within the current regulatory frame reveals common hitches in the course of development, translation, and clinical application. This paper suggests outlining a path from the few examples of successfully approved vs unsuccessful advanced therapies.
In the multitude of ongoing studies, few of them achieved positive results with a final treatment available to patients; this result was possible due to multidisciplinary teams working together from the beginning of the development and during the hard route to standardization and clinical application.
The root of success of an advanced therapy requires not only the inescapable scientific and biological knowledge but also requires several contributions as regulatory, ethical, medical, and bio-engineering expertise, from the real beginning. A strong scientific rationale and an integrated network of expertises would contribute to a successful investment of available resources in advanced therapy medicinal products and to a greater confidence in future medicine.
本综述重点介绍了先进治疗药物产品(ATMPs)从实验室到临床应用过程中存在的相关问题。当前监管框架下的再生医学在开发、转化和临床应用过程中暴露出一些常见问题。本文建议通过已成功获批与未成功的先进疗法的少数实例勾勒出一条路径。
在众多正在进行的研究中,只有少数研究取得了积极成果,并最终为患者提供了可用的治疗方法;这一结果的取得得益于多学科团队从开发之初就共同努力,并经历了标准化和临床应用的艰难过程。
先进疗法成功的根源不仅需要必不可少的科学和生物学知识,而且从一开始就需要监管、伦理、医学和生物工程等多方面的专业知识。强有力的科学依据和综合的专业知识网络将有助于在先进治疗药物产品中成功投入可用资源,并增强对未来医学的信心。